<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24780124</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1476-5381</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>171</Volume>
            <Issue>16</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>British journal of pharmacology</Title>
          <ISOAbbreviation>Br J Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations.</ArticleTitle>
        <Pagination>
          <StartPage>3801</StartPage>
          <EndPage>3813</EndPage>
          <MedlinePgn>3801-13</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/bph.12749</ELocationID>
        <Abstract>
          <AbstractText>The mammalian target of rapamycin (mTOR) plays an important role in the regulation of protein translation, cell growth and metabolism. The mTOR protein forms two distinct multi-subunit complexes: mTORC1 and mTORC2. The mTORC1 complex is activated by diverse stimuli, such as growth factors, nutrients, energy and stress signals; and essential signalling pathways, such as PI3K and MAPK, in order to control cell growth, proliferation and survival. mTORC1 also activates S6K1 and 4EBP1, which are involved in mRNA translation. The mTORC2 complex is resistant to rapamycin inhibitory activity and is generally insensitive to nutrient- and energy-dependent signals. It activates PKC-α and Akt and regulates the actin cytoskeleton. Deregulation of the mTOR-signalling pathway (PI3K amplification/mutation, PTEN loss of function, Akt overexpression, and S6K1, 4EBP1 and eIF4E overexpression) is common in cancer, and alterations in components of the mTOR pathway have a major role in tumour progression. Therefore, mTOR is an appealing therapeutic target in many tumours. Here we summarize the upstream regulators and downstream effectors of the mTORC1 and mTORC2 pathways, the role of mTOR in cancer, and the potential therapeutic values and issues related to the novel agents targeting the mTOR-signalling pathway.</AbstractText>
          <CopyrightInformation>© 2014 The British Pharmacological Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Moschetta</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Section of Internal Medicine, Department of Biomedical Sciences and Human Oncology, University of Bari Medical School 'Aldo Moro', Bari, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reale</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marasco</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vacca</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carratù</LastName>
            <ForeName>M R</ForeName>
            <Initials>MR</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Br J Pharmacol</MedlineTA>
        <NlmUniqueID>7502536</NlmUniqueID>
        <ISSNLinking>0007-1188</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046912" MajorTopicYN="N">Multiprotein Complexes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2014</Year>
          <Month>3</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>5</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24780124</ArticleId>
        <ArticleId IdType="pmc">PMC4128044</ArticleId>
        <ArticleId IdType="doi">10.1111/bph.12749</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B. Curr Biol. 1997;7:261–269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9094314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alvarado Y, Mita MM, Vemulapalli S, Mahalingam D, Mita AC. Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. Target Oncol. 2011;6:69–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21541789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, et al.  Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A. 2009;106:22299–22304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2799764</ArticleId>
            <ArticleId IdType="pubmed">20007781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Briest F, Grabowski P. PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine. Theranostics. 2014;4:336–365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3936289</ArticleId>
            <ArticleId IdType="pubmed">24578720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buerger C, DeVries B, Stambolic V. Localization of Rheb to the endomembrane is critical for its signaling function. Biochem Biophys Res Commun. 2006;344:869–880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16631613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capdevila J, Salazar R, Halperín I, Abad A, Yao JC. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. Cancer Metastasis Rev. 2011;30:27–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21311955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118:3065–3074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2518073</ArticleId>
            <ArticleId IdType="pubmed">18725988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng H, Walls M, Baxi SM, Yin MJ. Targeting the mTOR pathway in tumor malignancy. Curr Cancer Drug Targets. 2013;13:267–277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23297825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med. 2007;13:433–442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17905659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dann SG, Selvaraj A, Thomas G. mTOR complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med. 2007;13:252–259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17452018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De P, Miskimins K, Dey N, Leyland-Jones B. Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope. Cancer Treat Rev. 2013;39:403–412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23352077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, et al.  Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006;10:51–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2857533</ArticleId>
            <ArticleId IdType="pubmed">16843265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeGraffenried LA, Fulcher L, Friedrichs WE, Grünwald V, Ray RB, Hidalgo M. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol. 2004;15:1510–1516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15367412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dennis PB, Pullen N, Kozma SC, Thomas G. The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol Cell Biol. 1996;16:6242–6251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC231627</ArticleId>
            <ArticleId IdType="pubmed">8887654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dobbelstein M, Moll U. Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov. 2014;13:179–196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24577400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Don AS, Zheng XF. Recent clinical trials of mTOR-targeted cancer therapies. Rev Recent Clin Trials. 2011;6:24–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20868343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16847462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14:1351–1356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2683415</ArticleId>
            <ArticleId IdType="pubmed">19029981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5:671–688.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16883305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, et al.  Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocr Relat Cancer. 2005;12:983–998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16322337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E, et al.  Critical role for the p110-alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature. 2006;441:366–370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16625210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francipane MG, Lagasse E. Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1. Oncotarget. 2013;4:1948–1962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3875761</ArticleId>
            <ArticleId IdType="pubmed">24185040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, et al.  mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol. 2006;16:1865–1870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16919458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fruman DA, Bismuth G. Fine tuning the immune response with PI3K. Immunol Rev. 2009;228:253–272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19290933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Echeverria C. Blocking the mTOR pathway: a drug discovery perspective. Biochem Soc Trans. 2011;39:451–455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21428918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol. 2010;221:3–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2990190</ArticleId>
            <ArticleId IdType="pubmed">20225336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17613433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal. 2009;2:24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19383975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guertin DA, Guntur KV, Bell GW, Thoreen CC, Sabatini DM. Functional genomics identifies TOR-regulated genes that control growth and division. Curr Biol. 2006a;16:958–970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16713952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, et al.  Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 2006b;11:859–871.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17141160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, Qiu S, et al.  Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res. 2009;15:7207–7216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2898570</ArticleId>
            <ArticleId IdType="pubmed">19934294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, et al.  mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011;71:3246–3256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3085654</ArticleId>
            <ArticleId IdType="pubmed">21430067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, et al.  AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30:214–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2674027</ArticleId>
            <ArticleId IdType="pubmed">18439900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, et al.  Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110:177–189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardt M, Chantaravisoot N, Tamanoi F. Activating mutations of TOR (target of rapamycin) Genes Cells. 2011;16:141–151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3116645</ArticleId>
            <ArticleId IdType="pubmed">21210909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, et al.  The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004;166:213–223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2172316</ArticleId>
            <ArticleId IdType="pubmed">15249583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;16:392–395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2786175</ArticleId>
            <ArticleId IdType="pubmed">19587680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, et al.  The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011;332:1317–1322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3177140</ArticleId>
            <ArticleId IdType="pubmed">21659604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol. 2002;4:648–657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12172553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003;17:1829–1834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC196227</ArticleId>
            <ArticleId IdType="pubmed">12869586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, et al.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6:1122–1128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15467718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al.  SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006;127:125–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16962653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, et al.  Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010;16:205–213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4017764</ArticleId>
            <ArticleId IdType="pubmed">20072130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD, Pearson RB. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors. 2007;25:209–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18092230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S. Regulation of lifespan in drosophila by modulation of genes in the TOR signaling pathway. Curr Biol. 2004;14:885–890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2754830</ArticleId>
            <ArticleId IdType="pubmed">15186745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G, Mathew R, Jin S, et al.  Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev. 2007;21:1621–1635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1899472</ArticleId>
            <ArticleId IdType="pubmed">17606641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al.  mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110:163–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, et al.  GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell. 2003;11:895–904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12718876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ, et al.  Identification of a proline-rich Akt substrate as a 14–3-3 binding partner. J Biol Chem. 2003;278:10189–10194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12524439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122:3589–3594.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2758797</ArticleId>
            <ArticleId IdType="pubmed">19812304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3331679</ArticleId>
            <ArticleId IdType="pubmed">22500797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. 2005;56:47–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16039868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev. 2006;20:267–275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16452501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Liu J, Song J, Wang X, Weiss HL, Townsend CM, Jr, et al.  mTORC1 inhibition increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. Am J Physiol Cell Physiol. 2011;301:C213–C226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3129828</ArticleId>
            <ArticleId IdType="pubmed">21508335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Alafuzoff I, Soininen H, Winblad B, Pei JJ. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J. 2005;272:4211–4220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16098202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang C, Feng P, Ku B, Dotan I, Canaani D, Oh BH, et al.  Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat Cell Biol. 2006;8:688–699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16799551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16:64–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9140396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim HK, Choi YA, Park W, Lee T, Ryu SH, Kim SY, et al.  Phosphatidic acid regulates systemic inflammatory responses by modulating the Akt-mammalian target of rapamycin-p70 S6 kinase 1 pathway. J Biol Chem. 2003;278:45117–45127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12960176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu L, Luo Y, Chen L, Shen T, Xu B, Chen W, et al.  Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J Biol Chem. 2010;285:38362–38373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2992269</ArticleId>
            <ArticleId IdType="pubmed">20937815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009a;8:627–644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3142564</ArticleId>
            <ArticleId IdType="pubmed">19644473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS. mTOR Mediated Anti-Cancer Drug Discovery. Drug Discov Today Ther Strateg. 2009b;6:47–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2901551</ArticleId>
            <ArticleId IdType="pubmed">20622997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T, et al.  Discovery of 9-(6-aminopyridin-3-yl)-1-(3- (trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective and orally available mTOR inhibitor for treatment of cancer. J Med Chem. 2011;54:1473–1480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3090687</ArticleId>
            <ArticleId IdType="pubmed">21322566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, et al.  Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM and ATR. Cancer Res. 2013;73:2574–2586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3760004</ArticleId>
            <ArticleId IdType="pubmed">23436801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>López-Fauqued M, Gil R, Grueso J, Hernandez-Losa J, Pujol A, Moliné T, et al.  The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. Int J Cancer. 2010;126:1549–1561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19810100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, et al.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell. 2002;10:457–468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12408816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol. 2005;15:702–713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15854902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 2008;11:32–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2442829</ArticleId>
            <ArticleId IdType="pubmed">18166498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P, et al.  Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J. 2007;26:2527–2539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1868901</ArticleId>
            <ArticleId IdType="pubmed">17446862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Cantley LC. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci. 2003;28:573–576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14607085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin J, Masri J, Bernath A, Nishimura R, Gera J. Hsp70 associates with Rictor and is required for mTORC2 formation and activity. Biochem Biophys Res Commun. 2008;372:578–583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2512964</ArticleId>
            <ArticleId IdType="pubmed">18505677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meijer AJ, Codogno P. Regulation and role of autophagy in mammalian cells. Int J Biochem Cell Biol. 2004;36:2445–2462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15325584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27:2278–2287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2738634</ArticleId>
            <ArticleId IdType="pubmed">19332717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Milam MR, Celestino J, Wu W, Broaddus RR, Schmeler KM, Slomovitz BM, et al.  Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am J Obstet Gynecol. 2007;196:247.e1–2475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17346540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98:1817–1824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17888036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ, et al.  Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002;43:1170–1180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12177161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murata J, Tada M, Sawamura Y, Mitsumori K, Abe H, Nagashima K. Dysplastic gangliocytoma (Lhermitte-Duclos disease) associated with Cowden disease: report of a case and review of the literature for the genetic relationship between the two diseases. J Neurooncol. 1999;41:129–136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10222433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem. 2003;278:15461–15464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12604610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel V, Marsh CA, Dorsam RT, Mikelis CM, Masedunskas A, Amornphimoltham P. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res. 2011;71:7103–7112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3443559</ArticleId>
            <ArticleId IdType="pubmed">21975930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122:927–939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16179260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, Lawrence JC, et al.  Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature. 1994;371:762–767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7935836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschleger S, Deak M. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J. 2007;405:513–522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2267312</ArticleId>
            <ArticleId IdType="pubmed">17461779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009;137:873–886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2758791</ArticleId>
            <ArticleId IdType="pubmed">19446321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pópulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13:1886–1918.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3291999</ArticleId>
            <ArticleId IdType="pubmed">22408430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol. 2003;14:931–937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12796032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qu X, Zou Z, Sun Q, Luby-Phelps K, Cheng P, Hogan RN. Autophagy gene-dependent clearance of apoptotic cells during embryonic development. Cell. 2007;128:931–946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17350577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, et al.  Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009;8:1725–1738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2718129</ArticleId>
            <ArticleId IdType="pubmed">19584227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roper J, Richardson MP, Wang WV, Richard LG, Chen W, Coffee EM, et al.  The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS ONE. 2011;6:e25132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3180374</ArticleId>
            <ArticleId IdType="pubmed">21966435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6:729–734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16915295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, et al.  PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell. 2007;25:903–915.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17386266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al.  Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296–1302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15268862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor–mTOR complex. Science. 2005;307:1098–1101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15718470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schalm SS, Blenis J. Identification of a conserved motif required for mTOR signaling. Curr Biol. 2002;12:632–639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11967149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schalm SS, Fingar DC, Sabatini DM, Blenis J. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol. 2003;13:797–806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12747827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35:7S–14S.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12742462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seront E, Pinto A, Bouzin C, Bertrand L, Machiels J-P, Feron British O. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation. Br J Cancer. 2013;109:1586–1592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3777009</ArticleId>
            <ArticleId IdType="pubmed">23989949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, et al.  NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008;68:8022–8030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18829560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti A, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:15–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3291787</ArticleId>
            <ArticleId IdType="pubmed">22239438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seto B. Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer. Clin Transl Med. 2012;1:29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3561035</ArticleId>
            <ArticleId IdType="pubmed">23369283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol. 2004;14:1650–1656.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15380067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature. 2006;441:424–430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16724053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, et al.  The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6:91–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15261145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res. 2003;9:4340–4346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14555504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, et al.  Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 2002;62:5027–5034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12208757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle. 2009;8:3831–3837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19901542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonenberg N, Gingras AC. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol. 1998;10:268–275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9561852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9778245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science. 1997;277:567–570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9228007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev. 2009;35:148–159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19013721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi K, Nakagawa M, Young SG, Yamanaka S. Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway. J Biol Chem. 2005;280:32768–32774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16046393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature. 2012;485:109–113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3347774</ArticleId>
            <ArticleId IdType="pubmed">22552098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature. 2004;431:200–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15306821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab. 2006;3:393–402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16753575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signaling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol. 2007;9:316–323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17277771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest. 2011;121:1231–1241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3069769</ArticleId>
            <ArticleId IdType="pubmed">21490404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Harris TE, Roth RA, Lawrence JC., Jr PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem. 2007;282:20036–20044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17510057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med. 2011;52:497–500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21421716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S. Survival signaling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004;428:332–337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15029198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep. 2012;14:129–138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22350330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu JJ, Liu J, Chen EB, Wang JJ, Cao L, Narayan N, et al.  Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. Cell Rep. 2013;5:913–920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3784301</ArticleId>
            <ArticleId IdType="pubmed">23994476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16469695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Q, Inoki K, Ikenoue T, Guan KL. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 2006;20:2820–2832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1619946</ArticleId>
            <ArticleId IdType="pubmed">17043309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, et al.  Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009;69:6232–6240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19584280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villén J, et al.  Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 2011;332:1322–1326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3195509</ArticleId>
            <ArticleId IdType="pubmed">21659605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zask A, Verheijen JC, Curran K, Kaplan J, Richard DJ, Nowak P, et al.  ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines. J Med Chem. 2009;52:5013–5016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19645448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett. 2012;319:1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22261336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng X, Overmeyer JH, Maltese WA. Functional specificity of the mammalian Beclin-Vps34 PI 3-kinase complex in macroautophagy versus endocytosis and lysosomal enzyme trafficking. J Cell Sci. 2006;119:259–270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16390869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, et al.  Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 2007;109:3509–3512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1852241</ArticleId>
            <ArticleId IdType="pubmed">17179228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, et al.  PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest. 2007;117:730–738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1784000</ArticleId>
            <ArticleId IdType="pubmed">17290308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT, et al.  PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature. 2006;441:518–522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16633340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang YJ, Duan Y, Zheng XF. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today. 2011;16:325–331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3073023</ArticleId>
            <ArticleId IdType="pubmed">21333749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by association with the ribosome. Cell. 2011;144:757–768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3390257</ArticleId>
            <ArticleId IdType="pubmed">21157483</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
